<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082235</url>
  </required_header>
  <id_info>
    <org_study_id>E6742-A001-001</org_study_id>
    <nct_id>NCT03082235</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study E6742-A001-001 is a randomized, double-blind, placebo-controlled, single ascending dose&#xD;
      study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and&#xD;
      pharmacodynamics (PD) of single ascending oral doses of E6742 in healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 3, 2017</start_date>
  <completion_date type="Actual">October 11, 2017</completion_date>
  <primary_completion_date type="Actual">October 11, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with any serious adverse event and number of participants with any non-serious adverse event</measure>
    <time_frame>from Screening up to Day 7</time_frame>
    <description>The number of participants with any serious adverse event and the number of participants with any non-serious adverse event will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean maximum observed concentration (Cmax) of E6742 and the metabolite ER-1132963 in plasma</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 [7 days] and 2 [6 days]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time at which the highest drug concentration occurs (tmax) for E6742 and the metabolite ER-1132963 in plasma</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 [7 days] and 2 [6 days]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from zero time to 24 hours postdose (AUC[0-24h]) E6742 and the metabolite ER-1132963 in plasma</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 [7 days] and 2 [6 days]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from zero time to 72 hours postdose (AUC[0-72h]) for E6742 and the metabolite ER-1132963 in plasma</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 [7 days] and 2 [6 days]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from zero time to time of last quantifiable concentration (AUC[0-t]) for E6742 and the metabolite ER-1132963 in plasma</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 [7 days] and 2 [6 days]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from zero time extrapolated to infinite time (AUC[0-inf]) for E6742 and the metabolite ER-1132963 in plasma</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 [7 days] and 2 [6 days]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination phase half-life (t1/2) for E6742 and the metabolite ER-1132963 in plasma</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 [7 days] and 2 [6 days]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total clearance following extravascular administration (CL/F) for E6742 in plasma</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 [7 days] and 2 [6 days]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution at terminal phase (Vz/F) for E6742 in plasma</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 [7 days] and 2 [6 days]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC metabolite to E6742 ratio following molecular weight correction to E6742 equivalents in plasma</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 [7 days] and 2 [6 days]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of unchanged drug excreted in urine (Ae) for E6742 and the metabolite ER-1132963</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Cohorts 1, 2, 3, 5, and 6: Days 1 to 7: predose and 0 to 4, &gt;4 to 8, &gt;8 to 12, &gt;12 to 24, &gt;24 to 48, &gt;48 to 72, &gt;72 to 96, &gt;96 to 120, and &gt;120 to 144 hours postdose. Cohort 4: Days 1 to 7 (Treatment Period 1): predose and 0 to 4, &gt;4 to 8, &gt;8 to 12, &gt;12 to 24, &gt;24 to 48, &gt;48 to 72, &gt;72 to 96, &gt;96 to 120, and &gt;120 to 144 hours postdose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal clearance (CLR)</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Cohorts 1, 2, 3, 5, and 6: Days 1 to 7: predose and 0 to 4, &gt;4 to 8, &gt;8 to 12, &gt;12 to 24, &gt;24 to 48, &gt;48 to 72, &gt;72 to 96, &gt;96 to 120, and &gt;120 to 144 hours postdose. Cohort 4: Days 1 to 7 (Treatment Period 1): predose and 0 to 4, &gt;4 to 8, &gt;8 to 12, &gt;12 to 24, &gt;24 to 48, &gt;48 to 72, &gt;72 to 96, &gt;96 to 120, and &gt;120 to 144 hours postdose.</description>
  </primary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Cohort 1: 10 mg E6742</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 10 milligrams (mg) E6742 as a single oral dose in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single oral dose of placebo matching E6742 in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 25 mg E6742</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 25 mg E6742 as a single oral dose in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single oral dose of placebo matching E6742 in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: 50 mg E6742</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 50 mg E6742 as a single oral dose in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single oral dose of placebo matching E6742 in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: 100 mg E6742</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 100 mg E6742 as a single oral dose in the fasted state. Participants will then receive the same single oral dose of E6742 again in the fed state after a washout interval (at least 7 days or 5 half-lives of E6742, whichever is longer) for the evaluation of food effect.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single oral dose of placebo matching E6742 in the fasted state. Participants will then receive the same single oral dose of placebo again in the fed state after a washout interval (at least 7 days ) for the evaluation of food effect.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: 200 mg E6742</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 200 mg E6742 as a single oral dose in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single oral dose of placebo matching E6742 in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: 400 mg E6742</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 400 mg E6742 as a single oral dose in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single oral dose of placebo matching E6742 in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: 800 mg E6742</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 800 mg E6742 as a single oral dose in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single oral dose of placebo matching E6742 in the fasted state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E6742</intervention_name>
    <description>gelatin capsules</description>
    <arm_group_label>Cohort 1: 10 mg E6742</arm_group_label>
    <arm_group_label>Cohort 2: 25 mg E6742</arm_group_label>
    <arm_group_label>Cohort 3: 50 mg E6742</arm_group_label>
    <arm_group_label>Cohort 4: 100 mg E6742</arm_group_label>
    <arm_group_label>Cohort 5: 200 mg E6742</arm_group_label>
    <arm_group_label>Cohort 6: 400 mg E6742</arm_group_label>
    <arm_group_label>Cohort 7: 800 mg E6742</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>gelatin capsules</description>
    <arm_group_label>Cohort 1: Matching placebo</arm_group_label>
    <arm_group_label>Cohort 2: Matching placebo</arm_group_label>
    <arm_group_label>Cohort 3: Matching placebo</arm_group_label>
    <arm_group_label>Cohort 4: Matching placebo</arm_group_label>
    <arm_group_label>Cohort 5: Matching placebo</arm_group_label>
    <arm_group_label>Cohort 6: Matching placebo</arm_group_label>
    <arm_group_label>Cohort 7: Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Nonsmoking, male or female, age ≥18 years and ≤45 years old at the time of informed&#xD;
             consent&#xD;
&#xD;
          -  Body mass index (BMI) ≥18 and &lt;32 kilograms per meters squared (kg/m2) at Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a&#xD;
             positive beta-human chorionic gonadotropin [β-hCG] or human chorionic gonadotropin&#xD;
             [hCG] test with a minimum sensitivity of 25 International Units per Liter [IU/L] or&#xD;
             equivalent units of β-hCG [or hCG]). A separate baseline assessment is required if a&#xD;
             negative screening pregnancy test was obtained more than 72 hours before the first&#xD;
             dose of study drug.&#xD;
&#xD;
          -  Males who have not had a successful vasectomy (confirmed azoospermia) or they and&#xD;
             their female partners do not meet the criteria above (ie, not of childbearing&#xD;
             potential or practicing highly effective contraception throughout the study period and&#xD;
             for 5 times the half-life of the study drug plus 90 days after study drug&#xD;
             discontinuation). No sperm donation is allowed during the study period and for 5 times&#xD;
             the half-life of the study drug plus 90 days after study drug discontinuation.&#xD;
&#xD;
          -  Any history of gastrointestinal surgery that may affect pharmacokinetic (PK) profiles&#xD;
             of E6742 (eg, hepatectomy, nephrectomy, digestive organ resection) at Screening&#xD;
&#xD;
          -  A prolonged QTcF interval (QTcF &gt;450 ms) demonstrated on ECG at Screening or Baseline&#xD;
&#xD;
          -  Persistent systolic blood pressure &gt;130 mmHg or diastolic blood pressure &gt;85 mmHg&#xD;
             diastolic at Screening or Baseline Heart rate less than 50 or more than 100 beats/min&#xD;
             at Screening or Baseline&#xD;
&#xD;
          -  Known history of prolonged QT/QTc interval&#xD;
&#xD;
          -  Left bundle branch block&#xD;
&#xD;
          -  Known history of myocardial infarction or active ischemic heart disease&#xD;
&#xD;
          -  Known history of clinically significant arrhythmia or uncontrolled arrhythmia&#xD;
&#xD;
          -  Known history of clinically significant drug allergy at Screening&#xD;
&#xD;
          -  Known history of food allergies or presently experiencing significant seasonal or&#xD;
             perennial allergy at Screening&#xD;
&#xD;
          -  Known to be human immunodeficiency virus (HIV) positive at Screening&#xD;
&#xD;
          -  Active viral hepatitis (A, B, or C) as demonstrated by positive serology at Screening&#xD;
&#xD;
          -  History of drug or alcohol dependency or abuse within the 2 years prior to Screening,&#xD;
             or those who have a positive urine drug and alcohol test at Screening or Baseline&#xD;
&#xD;
          -  Intake of herbal preparations containing St. John's Wort within 4 weeks before dosing&#xD;
&#xD;
          -  Use of prescription drugs within 4 weeks before dosing&#xD;
&#xD;
          -  Intake of over-the-counter (OTC) medications within 2 weeks before dosing&#xD;
&#xD;
          -  Currently enrolled in another clinical study or used any investigational drug or&#xD;
             device within 30 days (or 5 half-lives, whichever is longer) before informed consent&#xD;
&#xD;
          -  Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or&#xD;
             donation of plasma within 1 week before dosing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Parexel International</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>September 6, 2018</last_update_submitted>
  <last_update_submitted_qc>September 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy participants</keyword>
  <keyword>E6742</keyword>
  <keyword>pharmacokinetics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

